Characteristics of Enrolled LA-ESCC Patients (n = 18)
| Characteristic | Patients (n) |
|---|---|
| Age (y) | |
| >60 | 12 (66.67%) |
| ≤60 | 6 (33.33%) |
| Sex | |
| Male | 12 (66.67%) |
| Female | 6 (33.33%) |
| Eastern Cooperative Oncology Group score | |
| 0 | 11 (61.11%) |
| 1 | 7 (38.89%) |
| T stage | |
| T2 | 1 (5.56%) |
| T3 | 14 (77.78%) |
| T4 | 3 (16.67%) |
| N stage | |
| N0 | 5 (27.78%) |
| N1 | 8 (44.44%) |
| N2 | 5 (27.78%) |
| Tumor site | |
| Cervical | 3 (16.67%) |
| Upper | 4 (22.22%) |
| Middle | 2 (11.11%) |
| Lower | 9 (50.00%) |
| Concomitant chemotherapy | |
| Docetaxel + carboplatin/nedaplatin | 2 (11.11%) |
| Paclitaxel + nedaplatin/carboplatin/cisplatin | 5 (27.78%) |
| Paclitaxel | 7 (38.89%) |
| Capecitabine | 1 (5.56%) |
| Tegafur | 1 (5.56%) |
| None | 2 (5.56%) |
| Short-term outcome (RECIST) | |
| Complete response | 0 |
| Partial response | 11 (61.11%) |
| Stable disease | 7 (38.89%) |
| Progressive disease | 0 |